TY - JOUR
T1 - Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
AU - Barros-Martins, Joana
AU - Hammerschmidt, Swantje I.
AU - Cossmann, Anne
AU - Odak, Ivan
AU - Stankov, Metodi V.
AU - Morillas Ramos, Gema
AU - Dopfer-Jablonka, Alexandra
AU - Heidemann, Annika
AU - Ritter, Christiane
AU - Friedrichsen, Michaela
AU - Schultze-Florey, Christian
AU - Ravens, Inga
AU - Willenzon, Stefanie
AU - Bubke, Anja
AU - Ristenpart, Jasmin
AU - Janssen, Anika
AU - Ssebyatika, George
AU - Bernhardt, Günter
AU - Münch, Jan
AU - Hoffmann, Markus
AU - Pöhlmann, Stefan
AU - Krey, Thomas
AU - Bošnjak, Berislav
AU - Förster, Reinhold
AU - Behrens, Georg M.N.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/9
Y1 - 2021/9
N2 - Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer’s BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.
AB - Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer’s BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.
UR - http://www.scopus.com/inward/record.url?scp=85111083355&partnerID=8YFLogxK
U2 - 10.1038/s41591-021-01449-9
DO - 10.1038/s41591-021-01449-9
M3 - Journal articles
C2 - 34262158
AN - SCOPUS:85111083355
SN - 1078-8956
VL - 27
SP - 1525
EP - 1529
JO - Nature Medicine
JF - Nature Medicine
IS - 9
ER -
